User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Primary tabs

download
  • Open access
  • PDF
  • 514.74 K
Gold, Ralf Kappos, Ludwig Arnold, Douglas L Bar-Or, Amit Giovannoni, Gavin Sindic, Christian [UCL]

In patients with relapsing-remitting multiple sclerosis, both BG-12 regimens, as compared with placebo, significantly reduced the proportion of patients who had a relapse, the annualized relapse rate, the rate of disability progression, and the number of lesions on MRI. (Funded by Biogen Idec; DEFINE ClinicalTrials.gov number, NCT00420212.).

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès libre
Publication date 2012
Language Anglais
Journal information "New England Journal of Medicine" - Vol. 367, no.12, p. 1098-107 (2012)
Peer reviewed yes
Publisher Massachusetts Medical Society
issn 1533-4406
Publication status Publié
Affiliation UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire
MESH Subject Administration, Oral ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multiple Sclerosis, Relapsing-Remitting ; Adult ; Brain ; Double-Blind Method ; Female ; Fumarates ; Humans ; Immunosuppressive Agents ; Infection
Links
Bibliographic reference Gold, Ralf ; Kappos, Ludwig ; Arnold, Douglas L ; Bar-Or, Amit ; Giovannoni, Gavin ; et. al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.. In: New England Journal of Medicine, Vol. 367, no.12, p. 1098-107 (2012)
Permanent URL http://hdl.handle.net/2078.1/124401